XML 40 R30.htm IDEA: XBRL DOCUMENT
v3.22.2.2

REVENUES (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Revenue from Contract with Customer [Abstract] |
Contract with Customer, Contract Asset | The following table summarizes our contract assets:
(in millions) | September 30, 2022 | December 31, 2021
Contract manufacturing services | $ | 65 |  | $ | 50 |
Software sales | 44 |  | 45 |
Bundled equipment and consumable medical products contracts | 120 |  | 100 |
Contract assets | $ | 229 |  | $ | 195 |
The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:
(in millions) | September 30, 2022 | December 31, 2021
Prepaid expenses and other current assets | $ | 106 |  | $ | 84 |
Other non-current assets | 123 |  | 111 |
Contract assets | $ | 229 |  | $ | 195 |
Accrued expenses and other current liabilities | $ | 158 |  | $ | 162 |
Other non-current liabilities | 82 |  | 84 |
Contract liabilities | $ | 240 |  | $ | 246 |
The following table summarizes contract liability activity for the nine months ended September 30, 2022. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
| Nine months ended September 30, 2022
Balance at beginning of period | $ | 246 |
New revenue deferrals | 460 |
Revenue recognized upon satisfaction of performance obligations | (463) |
Currency translation | (3) |
Balance at end of period | $ | 240 |
Net Sales from Contracts with Customers by Global Business Unit | The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:
| Three Months Ended September 30,
| 2022 | 2021
(in millions) | U.S. | International | Total | U.S. | International | Total
Renal Care 1 | $ | 240 |  | $ | 702 |  | $ | 942 |  | $ | 222 |  | $ | 759 |  | $ | 981 |
Medication Delivery 2 | 475 |  | 250 |  | 725 |  | 490 |  | 257 |  | 747 |
Pharmaceuticals 3 | 173 |  | 352 |  | 525 |  | 188 |  | 401 |  | 589 |
Clinical Nutrition 4 | 92 |  | 139 |  | 231 |  | 88 |  | 156 |  | 244 |
Advanced Surgery 5 | 141 |  | 106 |  | 247 |  | 135 |  | 114 |  | 249 |
Acute Therapies 6 | 53 |  | 105 |  | 158 |  | 69 |  | 116 |  | 185 |
BioPharma Solutions 7 | 99 |  | 73 |  | 172 |  | 109 |  | 97 |  | 206 |
Patient Support Systems 8 | 301 |  | 79 |  | 380 |  | — |  | — |  | — |
Front Line Care 9 | 209 |  | 70 |  | 279 |  | — |  | — |  | — |
Surgical Solutions 10 | 38 |  | 38 |  | 76 |  | — |  | — |  | — |
Other 11 | 28 |  | 10 |  | 38 |  | 18 |  | 7 |  | 25 |
Total Baxter | $ | 1,849 |  | $ | 1,924 |  | $ | 3,773 |  | $ | 1,319 |  | $ | 1,907 |  | $ | 3,226 |
| Nine Months Ended September 30,
| 2022 | 2021
(in millions) | U.S. | International | Total | U.S. | International | Total
Renal Care 1 | $ | 690 |  | $ | 2,077 |  | $ | 2,767 |  | $ | 655 |  | $ | 2,212 |  | $ | 2,867 |
Medication Delivery 2 | 1,406 |  | 735 |  | 2,141 |  | 1,345 |  | 751 |  | 2,096 |
Pharmaceuticals 3 | 494 |  | 1,080 |  | 1,574 |  | 550 |  | 1,137 |  | 1,687 |
Clinical Nutrition 4 | 266 |  | 422 |  | 688 |  | 255 |  | 460 |  | 715 |
Advanced Surgery 5 | 428 |  | 310 |  | 738 |  | 405 |  | 317 |  | 722 |
Acute Therapies 6 | 179 |  | 340 |  | 519 |  | 211 |  | 369 |  | 580 |
BioPharma Solutions 7 | 226 |  | 265 |  | 491 |  | 218 |  | 306 |  | 524 |
Patient Support Systems 8 | 880 |  | 247 |  | 1,127 |  | — |  | — |  | — |
Front Line Care 9 | 618 |  | 237 |  | 855 |  | — |  | — |  | — |
Surgical Solutions 10 | 111 |  | 112 |  | 223 |  | — |  | — |  | — |
Other 11 | 72 |  | 31 |  | 103 |  | 58 |  | 21 |  | 79 |
Total Baxter | $ | 5,370 |  | $ | 5,856 |  | $ | 11,226 |  | $ | 3,697 |  | $ | 5,573 |  | $ | 9,270 |
1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. 2 Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices. 3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. 4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products. 5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. 6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU). 7 BioPharma Solutions includes sales of contracted services we provide to various pharmaceutical and biopharmaceutical companies. 8 Patient Support Systems includes sales of our connected care solutions: devices, software, communications and integration technologies and smart beds. 9 Front Line Care includes sales of our integrated patient monitoring and diagnostic technologies to help diagnose, treat and manage a wide variety of illness and diseases, including respiratory therapy, cardiology, vision screening and physical assessment. 10 Surgical Solutions includes sales of our surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. 11 Other includes sales of miscellaneous product and service offerings.
Sales-type Lease, Lease Income | The components of lease revenue for the three and nine months ended September 30, 2022 and 2021 were:
(in millions) | Three months ended September 30, 2022 | Nine months ended September 30, 2022
Sales-type lease revenue | $ | 3 |  | $ | 11 |
Operating lease revenue | 145 |  | 380 |
Variable lease revenue | 9 |  | 41 |
Total lease revenue | $ | 157 |  | $ | 432 |
(in millions) | Three months ended September 30, 2021 | Nine months ended September 30, 2021
Sales-type lease revenue | $ | 3 |  | $ | 19 |
Operating lease revenue | 21 |  | 90 |
Variable lease revenue | 27 |  | 59 |
Total lease revenue | $ | 51 |  | $ | 168 |
Operating Lease, Lease Income | The components of lease revenue for the three and nine months ended September 30, 2022 and 2021 were:
(in millions) | Three months ended September 30, 2022 | Nine months ended September 30, 2022
Sales-type lease revenue | $ | 3 |  | $ | 11 |
Operating lease revenue | 145 |  | 380 |
Variable lease revenue | 9 |  | 41 |
Total lease revenue | $ | 157 |  | $ | 432 |
(in millions) | Three months ended September 30, 2021 | Nine months ended September 30, 2021
Sales-type lease revenue | $ | 3 |  | $ | 19 |
Operating lease revenue | 21 |  | 90 |
Variable lease revenue | 27 |  | 59 |
Total lease revenue | $ | 51 |  | $ | 168 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 30 -Section 50 -Paragraph 12 -URI https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981 + Details
Name: | us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 30 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981 + Details
Name: | us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration